Drug Profile
Research programme: receptor tyrosine kinase inhibitors - ChemDiv/Oncalis
Alternative Names: ONC-101Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator ChemDiv; Oncalis
- Class Small molecules
- Mechanism of Action EphB4 inhibitors; Epidermal growth factor inhibitors; Raf kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Switzerland (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 29 Oct 2008 Preclinical development is ongoing in USA and Switzerland